Survival and Toxicities after Yttrium-90 Transarterial Radioembolization of Cholangiocarcinoma in the RESiN Registry. Journal of vascular and interventional radiology : JVIR Robinson, T. J., Du, L., Matsuoka, L., Sze, D. Y., Kennedy, A. S., Gandhi, R. T., Kouri, B. E., Collins, Z. S., Kokabi, N., Grilli, C. J., Wang, E. A., Lee, J. S., Brown, D. B. 2022


To report outcomes in cholangiocarcinoma patients treated with 90Y resin microspheres (TARE) from a multicenter, prospective observational registry.Ninety-five patients (median age 67 years [IQR: 67, 74]; 50 men) were treated in 27 centers between July 2015-August 2020. Baseline demographics included imaging findings, performance status and previous systemic or locoregional treatments. Dosimetry method was tracked. Overall Survival (OS)/Progression Free Survival (PFS) were calculated by the Kaplan-Meier method. Best imaging response was calculated with RECIST 1.1. Grade >/=3 toxicities were assessed using CTCAE v5. Cox regression analysis was performed.Sixty percent (52/86) patients had multifocal and 27% had extrahepatic tumor. The median index tumor diameter was 7.0 cm (IQR: 4.9-10). Activity calculation method was reported in 59 (62%) patients with body-surface area (BSA) most used (45/59, 76%). Median OS for the cohort was 14 months (95% CI, 12-22). OS at 3, 6, 12, and 24 months was 94%, 80%, 63% and 34%. Median OS was longer in patients without cirrhosis (19.1 vs 12.2 months, p=0.05). Cirrhosis, previous chemotherapy (OS 19.1 vs 10.6 months for treatment naïve, p=0.07) and imaging response at 6 months (OS 16.4 vs. 9.5 months for no response, p=0.06) underwent regression analysis. Imaging response predicted OS at regression (HR: 0.39, p=0.008). Grade 3-4 bilirubin toxicities were seen in 5/72 (7%) patients. Grade 3 albumin toxicity was seen in 1/72 (1.4%) patients.Objective response at 6 months predicts longer OS with TARE for cholangiocarcinoma. Liver function toxicity incidence is <10%.

View details for DOI 10.1016/j.jvir.2022.10.042

View details for PubMedID 36509236